Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

Analysts have been eager to weigh in on the Communication Services sector with new ratings on DoorDash (DASH – Research Report), T Mobile US (TMUS – Research Report) and Telef ...

Though there were no historical benchmarks to gauge the response, the Dollar Index could fall more than 5%. Sterling edged higher versus the euro but remained weaker against a firmer dollar after the ...

The airline reset its profit guidance for the year, citing improved travel appetite after economic turmoil and flight disruptions depressed bookings this spring. Coca-Cola says more details are to ...